ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2021. The put-call ratio across all filers is 8.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,832 | -39.0% | 81 | -25.7% | 0.00% | – |
| Q1 2022 | $7,916 | -3.0% | 109 | +12.4% | 0.00% | – |
| Q4 2021 | $8,157 | +17.5% | 97 | +26.0% | 0.00% | – |
| Q3 2021 | $6,945 | +4.0% | 77 | +10.0% | 0.00% | – |
| Q2 2021 | $6,675 | -11.2% | 70 | +6.1% | 0.00% | – |
| Q1 2021 | $7,515 | +59.7% | 66 | +94.1% | 0.00% | – |
| Q4 2020 | $4,707 | +84.7% | 34 | +9.7% | 0.00% | – |
| Q3 2020 | $2,548 | -87.4% | 31 | -93.4% | 0.00% | -100.0% |
| Q3 2019 | $20,192 | -31.3% | 472 | +1.9% | 0.00% | 0.0% |
| Q2 2019 | $29,401 | -6.2% | 463 | +2.4% | 0.00% | -33.3% |
| Q1 2019 | $31,351 | +54.1% | 452 | -3.4% | 0.00% | 0.0% |
| Q4 2018 | $20,349 | – | 468 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |